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ABSTRACT 
Objectives: Osteoarthritis (OA) is a leading cause of disability, but the relationship with premature 
mortality remains uncertain. We aimed to investigate the relationship between OA and mortality 
from any cause and from cardiovascular disease (CVD).  M ethods: E    
searches were conducted to identify prospective studies comparing mortality in a sample of people 
with and without OA. Risk of all-cause and CVD mortality were summarized using adjusted hazard 
ratios (HRs) for joint specific (hand, hip, and knee) and joint non-specific OA. New data from the 
Progetto Veneto Anziani (PRO.V.A.) study were also included. Results: From the PRO.V.A. study 
(N 1⁄4 2927), there was no significant increase in mortality risk for participants with any joint OA 
(N 1⁄4 1858) compared to non-OA (all-cause, HR 1⁄4 0.95, 95% CI: 0.77–1.15 and CVD, HR 1⁄4 
1.12, 95% CI: 0.82–1.54). On meta-analysis, seven studies (OA 1⁄4 10,018/non-OA 1⁄4 18,541), 
with a median 12-year follow-up, reported no increased risk of any-cause mortality in those with 
OA (HR 1⁄4 1.10, 95% CI: 0.97–1.25). After removing data on hand OA, a significant association 
between OA and mortality was observed (HR 1⁄4 1.18, 95% CI: 1.08–1.28). There was a significant 
higher risk of overall mortality for (1) studies conducted in Europe, (2) patients with multi-joint 
OA; and (3) a radiological diagnosis of OA. OA was associated with significantly higher CVD 
mortality (HR 1⁄4 1.21, 95% CI: 1.10–1.34).  
Conclusions: People with OA are at increased risk of death due to CVD. The relationship with 
overall mortality is less clear and may be moderated by the presence of hand OA.  
INTRODUCTION 
Osteoarthritis (OA) is a leading cause of years lived with disability worldwide [1,2]. The leading symptom 
associated with OA is chronic musculoskeletal pain, which is associated with mobility and function [3,4]. 
Physical inactivity is independently associated with an increased risk of cardiovascular diseases (CVD) and 
mortality in the general population [5]. Obesity is also commonly seen within the osteoarthritis population, while 
also being associated with morbidities such as type two diabetes, cancers, and CVD [6].  
CVD are a leading cause of global mortality, with recent estimates demonstrating that CVD account for 17.3 
million deaths globally [7]. A recent meta-analysis demonstrated that people with OA are at increased risk of 
CVDs [8], which may also be influenced by an elevated chronic inflammatory status in some subgroups with OA 
[9]. Death due to CVD is potentially prevent- able through appropriate timely pharmacological and non- 
pharmacological interventions [10]. Therefore, to identify people at higher risk of CVD mortality could be of 
considerable public health importance.  
Within the past decade, a number of observational studies have reported that people with OA are at increased risk 
of premature mortality compared to the general population [11–13]. However, this evidence is heterogeneous and 
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limited by the lack of adjust- ment for appropriate confounders.  
Given this, the purpose of this study was to (i) analyze data from a prospective cohort study on the risk of CVD 
mortality in OA compared to a non-osteoarthritis cohort, adjusting for important medical morbidities and other 
confounders; (ii) to systematically review the available literature and perform a meta-analysis to determine 
whether people with OA present a differential risk of overall and CVD mortality than those without OA. We 
hypothe- sized that people with OA had a significant higher risk of overall and CVD death compared to those 
without OA.  
 
MATERIALS AND METHODS 
 
Prospective cohort study  
Overall cohort  
Previously unpublished data from the Progetto Veneto Anziani (PRO.V.A. study) were used to investigate the risk 
of overall and CVD mortality in people with OA over a mean follow-up of 4.4 years. The Pro.V.A. study is an 
observational cohort study on the Italian population aged over 65 years. The study population initially included 
3099 older Caucasian adults (1245 men/1854 women), who were randomly selected between 1995 and 1997 using 
a multistage stratified method, in two North Italian towns (Camposampiero and Rovigo). Additional details about 
the study design have been previously reported [14].  
Participant selection  
After excluding 172 participants without information about OA, data from 2927 participants (men 1⁄4 
1179/women 1⁄4 1748) were gathered. Hand, hip, and knee OA presence was assessed through medical history 
and records, previous x-ray reports, and clinical evaluation. This latter evaluation included for the hand the 
presence of Heberden nodes, stiffness, and pain at passive moment; for the knee—deformity, pain at passive 
movement, reduced passive mobility, and crepitus; for the hip—pain at passive movement, rotation and palpation, 
and reduced external rotation. The diagnosis of OA was finally confirmed by a rheumatologist using a 
standardized algorithm [15]. Mortality was ascertained through direct reviewing of single death certif- icate, and 
the main cause of death was recorded using the ICD-9. Death for CVD reasons was defined using the ICD-9 
codes from 390 to 459.  
Statistical analysis  
Owing to the small number of death attributed to non-CVD, it was not possible to appropriate analyses overall 
mortality, over CVD mortality from this dataset. Accordingly, the risk of CVD mortality associated with OA was 
investigated using multivariate  
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Cox’s regression analysis adjusted for known clinical factors associated with mortality. These included age 
(continuous); gen- der; body mass index (continuous); educational level ( r 5 vs. 4 5 years); alcohol drinking (yes 
vs. no); monthly income ( Z 500 vs. o 500 €); physical activity level ( Z 4 vs. o 4 h/week); presence at baseline of 
CVD, fractures, chronic obstructive pulmonary disease, orthostatic hypotension (difference in systolic of 20 
mmHg or diastolic of 10mmHg between orthostatism and clinostatism) [16], hypertension (use of anti-
hypertensive medications, mean of systolic blood pressure Z140, or mean diastolic blood pressure Z 90 mmHg) 
[17], diabetes (fasting plasma glucose Z 126 mg/dl, glycosilated hemoglobin Z7% or use of anti-diabetic 
medications) [18], frailty (according with a modified Fried’s index) [19], and cancer (all yes vs. no); number of 
medications (continuous); smoking status (current/former vs. never); and activities of daily living assessed 
(ADLs) [20], Mini-Mental State Examination (MMSE) [21], Geriatric Depression Scale [22], and Geriatric Nutri- 
tion Risk Index scores (GNRI) [23] (all as continuous). For all the scores, with exception of GDS, the higher the 
score the better the status. In the multivariate analysis, data were missing for 258 ( 1⁄4 8.8%) of the participants, 
mainly for information about ortho- static hypotension (n 1⁄4 142), glycosilated hemoglobin (n 1⁄4 244), and 
MMSE (n 1⁄4 125).  
Risk estimates were computed for any joint and anatomical region affected (hand, hip, or knee). All analyses were 
performed using the SPSS 21.0 for Windows (SPSS Inc., Chicago, IL). Statistical significance was assumed for a 
two-tailed p o 0.05.  
Systematic review  
This systematic review was conducted following the MOOSE (meta-analysis of observational studies in 
epidemiology) guide- lines and data reporting was performed in agreement with the PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [24,25].  
Data sources and literature search strategy  
We created search strategies for the concepts of “osteoarthritis” and “mortality” using a combination of 
standardized terms and keywords harvested from indices, thesauri, and on-topic articles (Supplementary Table 1). 
The electronic databases [PubMed, Embase, Scopus, CiNAHL (via Ebsco), ASSIA (via Proquest), and Social 
Work Abstracts (via Ebsco)], were search from database inception to November 17, 2015. We further conducted a 
manual search of reference lists of included and other relevant articles. Authors were contacted in case of lacking 
information. All articles were reviewed for inclusion by two independent reviewers (N.V. and B.S.). Any 
discrepancies were resolved by consensus with a third reviewer (E.M.).  
Study selection  
Prospective, observational cohort studies were eligible for inclusion if they reported data on OA diagnosed with 
clinical and/or radiological assessment; reported mortality risk estimates [hazard ratios (HRs)] along with their 
95% CI; and included a control group without OA. Intervention studies and studies includ- ing only participants 
with joint replacement (e.g., total hip or total knee arthroplasty) were excluded.  
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Data extraction  
Overall and CVD risk estimates (adjusted for the maximum number of confounders available) comparing people 
with OA against people without OA were gathered. One investigator (N.V.) extracted data from the included 
articles and two independent investigators (C.L. and E.C.) verified these data. For each article we also extracted 
data about authors, publication year, study location, setting, and participant characteristics by presence of OA 
[e.g., age, percentage of women, CVD, body mass index (BMI)], follow-up duration (in years), number, and list 
of covariates used in statistical analyses. Study authors were contacted if necessary.  
Outcomes  
The primary outcome included overall mortality in OA com- pared to non-OA participants. Secondary outcomes 
included over- all mortality based on anatomical site of OA (i.e., hand, hip, and knee) and CVD mortality.  
Assessment of study quality  
The Newcastle–Ottawa Scale (NOS) [26] was used to evaluate study quality. The NOS assigns a maximum of 
nine points to studies of highest quality according to the following three quality parameters: selection (four 
points), comparability (two points), and outcome (three points). Each included study was assessed by three 
reviewers. If discrepancies arose in appraisal, these were addressed by a joint re-evaluation of the article (M.S., 
S.M., and T.S.).  
Data synthesis and statistical analysis  
To compensate for potential between study heterogeneity, we calculated a pooled HR using DerSimonian–Laird 
random-effect model [27]. Statistical heterogeneity across studies was assessed using the Cochrane I2 metric and 
chi-square statistics [28]. Since the diagnostic criteria for OA involve clinical and radiological parameters [29–31] 
and evidence has suggested that radiological findings may poorly correlate to clinical presentation [32], in 
absence of universally agreed recommendations we initially (pri- mary analyses) pooled HRs of overall mortality 
as provided by the studies regardless of method of diagnosis. Joint specific estimates for overall mortality and 
CVD-specific death were computed. Within-study pooled estimates were also calculated as necessary (e.g., only 
joint-specific HRs provided).  
Given significant statistical heterogeneity (I2 Z 50%) [33], we conducted meta-regression analyses investigating 
the following moderators: continent (Europe vs. others), type of diagnosis of OA (clinical vs. radiological vs. 
combined); follow-up duration, NOS score, number of adjustments (all by median value), death ascer- tainment 
(using death certificates or other tools), and number of sites affected.  
Publication bias was assessed by visually inspecting funnel plots and using the Begg and Mazumdar’s Kendall tau 
[34] and the Egger’s bias test [35]. To account for potential publication bias, we used a “trim-and-fill” method, 
based on the assumption that the effect sizes of all the studies are normally distributed around the center of a 
funnel plot. In the event of asymmetries, this procedure adjusts for the potential effect of unpublished (imputed) 
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studies [36]. All analyses were performed using Comprehensive Meta-Analysis 3.  
Results  
Prospective cohort study  
Baseline characteristics In the PRO.V.A. study, participants with OA (N 1⁄4 1858; 63.5%)  
were significantly older, with a greater proportion of women compared to those without OA (n 1⁄4 1069) (Table 
1). Subjects with OA had also a significantly higher presence of potential risk factors for early mortality; 
including lower GNRI, preserved number of ADLs, and higher presence of depressive symptoms; frailty, osteo- 
porotic fractures, orthostatic hypotension and hypertension, dia- betes, and CVD, compared to the non-OA group 
(Table 1).  
Follow-up and CVD mortality  
Over the 4.4 years of follow-up, 745 participants (men 1⁄4 380/ women 1⁄4 365) died. Using Cox’s regression 
analysis and taking participants with no OA for reference, no significant increased risk of death in people with OA 
emerged [HR 1⁄4 0.95 (95% CI: 0.77–1.15); p 1⁄4 0.58] (Table 2). On the multivariate analysis (Supplementary 
Table 2), the significant predictors of death were diabetes [HR 1⁄4 1.50 (95% CI: 1.20–1.88); p o 0.001], CVD 
[HR 1⁄4 1.50 (95% CI: 1.23–1.82); p o 0.001], COPD [HR 1⁄4 1.34 (95% CI: 1.04–1.72); p 1⁄4 0.03], cancer [HR 
1⁄4 1.37 (95% CI: 1.03–1.81); p 1⁄4 0.03], and frailty [HR 1⁄4 2.12 (95% CI: 1.52–2.97); p o 0.001]. Higher 
MMSE and GNRI were protective for mortality [HR 1⁄4 0.96 (95% CI: 0.94–0.98); p o 0.001 and HR 1⁄4 0.96 
(95% CI: 0.95–0.97); p o 0.001, respectively]. A similar lack of association was also found when individually 
analyzing OA by anatomical site (hand, hip, or knee) or when lower limbs OA was analyzed [HR 1⁄4 0.97 (95% 
CI: 0.82–1.14); p 1⁄4 0.48]. Finally, OA did not significantly increase the risk of CVD death [total number of 
events, n 1⁄4 373; HR 1⁄4 1.12 (95% CI: 0.83–1.55); p 1⁄4 0.53]. Other causes of death could not be investigated 
(respiratory, n 1⁄4 128; cancer, n 1⁄4 58; and others 1⁄4 186).  
Systematic review  
Search results  
In total, 2139 non-duplicated articles were identified. After excluding 2124 articles based on title/abstract review, 
15 articles were fully retrieved and six were included [37–42] along with data from the PRO.V.A study 
(Supplementary Fig.). For one conference abstract [38], additional data were gathered from the authors.  
Study and population characteristics  
As reported in Table 3, the seven meta-analyzed studies followed 28,559 participants (OA 1⁄4 10,018/non-OA 1⁄4 
18,541) for a median duration of 12 (IQR: 6.5–18) years. Participants were all community dwellers, mainly 
European (N 1⁄4 4; 57%). The assess- ment of OA was heterogeneous across studies with two [37,38] and five 
(PRO.V.A and [39–42]) reporting a radiological and a combined (clinical þ radiological) assessment, respectively. 
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Differ- ent methods of death ascertainment were also observed, but six out of seven were of high reliability and 
quality [37–41]. Finally, four of the included studies also provided data for CVD mortality (PRO.V.A and 
[37,38,41]).  
Quality assessment  
The median NOS score was seven (IQR: 6–8). The most common source of bias was the ascertainment of 
exposure (particularly missing data on radiological or standardized criteria for the assessment of OA; 
Supplementary Table 3). On the other, only one study has not considered pertinent linkage to high-quality records 
[42].  
Hazard ratios for overall mortality  
For the calculation of pooled overall mortality estimate we used joint-specific HRs for three studies [40–42]. 
Compared to those without OA, participants with OA had no significantly different risk for overall mortality (HR 
1⁄4 1.10; 95% CI: 0.97–1.25; p 1⁄4 0.12; I2 1⁄4 67%; Fig.), also after adjusting for a median of 13 (IQR: 9–14) 
confounders (Supplementary Table 4). After excluding studies providing risks for site specific OA, the pooled risk 
of death from all causes was found to be significant with low heterogeneity (HR 1⁄4 1.18; 95% CI: 1.08–1.28; p o 
0.001; I2 1⁄4 47%).  
Subgroup analyses demonstrated that the presence of OA in hand, hip, and knee was not associated with an 
increased risk of mortality (Fig.). Funnel plot inspection indicated that publication bias was unlikely, as confirmed 
by Begg’s (p 1⁄4 0.90) and Egger’s tests (p 1⁄4 0.89).  
Hazard ratios for cause-specific (CVD) mortality In four studies (PRO.V.A and [37,38,41]), OA was significantly  
associated with CVD death without heterogeneity or publication bias (HR 1⁄4 1.21; 95% CI: 1.10–1.34; p o 0.001; 
I2 1⁄4 0%). Cause- specific mortality for single joints could not be computed due to the limited number of studies.  
Meta-regression analysis  
As the overall mortality analyses showed evidence of hetero- geneity (I2 1⁄4 67%), a meta-regression analysis was 
undertaken (Table 4). In a great part of the strata heterogeneity remained high. However, in some studies there 
was a significantly higher risk of overall mortality and a moderate to substantial reduction of between-study 
heterogeneity—European studies; death ascertain- ment using death certificates; multiple joints affected; and 
radio- logical diagnosis of OA.  
As the pooled HR for hand OA on overall mortality appeared to be marginally protective (p 1⁄4 0.07), a sensitivity 
analysis was conducted to remove the effect of three datasets (PRO.V.A and [40,41]). This analysis demonstrated 
that for hand OA, pooled HR for mortality was 1.18 (95% CI: 1.07–1.30; p 1⁄4 0.001; I2 1⁄4 48%) (PRO.V.A and 
[33–35,37,38]).  
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Discussion   
To the best of our knowledge, this is the first meta-analysis investigating the association between OA and 
mortality. The seven meta-analyzed studies (including 10,018 participants with and 18,541 people without OA) 
demonstrated that the presence of OA was not associated with mortality, although this appeared to substantially 
depend on between-study heterogeneity. When analyzing studies conducted in Europe, we observed a 
significantly higher risk of mortality and lower heterogeneity. A significant  
confounding factor to mortality seems to be the inclusion of the studies reporting data on hand OA. Finally, when 
considering cause-specific mortality, it appears that people with OA are at increased risk of CVD mortality.  
It is known that participants with OA frequently exhibit a number of medical morbidities which increase their risk 
for death [8,39,43]. In the PRO.V.A. study, people with OA reported a higher presence of frailty, cardiovascular 
and metabolic diseases than those without. The role of these potential confounders in explain- ing the relationship 
between OA and mortality seems to be relevant [44], consistent with the findings of a recent large scale 
prospective study [37] reinforcing the importance of CVD risk in influencing mortality of people with OA. In the 
PRO.V.A. study we have tried to better identify the specific risk factors for mortality in participants with OA, in 
order to propose appropriate and specific interventions. Independent predictors of early death significantly 
different between those with OA and those without were diabetes, CVD, frailty, and poorer nutrition index. 
Hierarchi- cally, frailty seems to be the most important and, since frailty is reversible if appropriately treated [45], 
our findings suggest that people with OA should be more active to reduce the risk of premature death. Thus, the 
association between OA and overall mortality appears to be more related to confounders than for OA itself. This 
is likely supported in our meta-analysis by strata analysis as the number of adjustments appeared to partially 
explain between-study heterogeneity. Strata analyses suggested not only that ethnicity could be a potential risk 
modifier but also that evidence of an association may depend on study method- ology. Particularly, our study 
highlights the need of providing evidence based or at least consensus-based criteria for homoge- nous case 
ascertainment.  
The secondary analyses explored whether the anatomical site of OA was associated with earlier mortality. Hip or 
knee OA did not predict early death, while for hand OA there was a trend towards a significant reduction in 
mortality. Since lower limbs OA are associated with high rate of disability and other risk factors for mortality 
[46], more research is needed to better understand the role of lower limbs OA in predicting mortality. Regarding 
hand OA, one study [40] suggests that not only radiographic but also symptomatic hand OA is protective for 
mortality, although both these conditions are associated with a higher incidence of CVD [40]. A possible reason is 
that hand OA was associated with a reduced cancer-related mortality [40]. The reasons of this associ- ation are not 
known and further research is obviously needed.  
Our data from the meta-analysis suggests that people with OA are at increased risk of premature mortality due to 
CVD also after accounting for potential confounders. People with OA are known to have high levels of CVD 
[8,47], an increased inflammatory profile [9] and low levels of physical activity [48], all of which may predispose 
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people with OA to premature mortality due to CVD. Moreover, they use a higher proportion of analgesic medi- 
cations with an unfavorable CVD profile [49].Given that exercise has been reported as being equally effective in 
managing some types of CVD as pharmacological interventions [50], interventions targeting physical activity, 
frailty, and inappropriate medication should be a priority among people with OA at higher risk of mortality. An 
indirect confirmation of this hypothesis was given by a recent study showing that patients with knee OA who 
under- went joint replacement had a lower risk of future CVD events, potentially due to an increased post-
operative physical activity levels and decreased use of analgesics when compared pre- operatively [51].  
While our primary data and meta-analyses are novel, the findings of our work should be interpreted within its 
limitations. First, there was some evidence of statistical heterogeneity. How- ever, we attempted to address the 
issue of between study hetero- geneity, as advised by the MOOSE guidelines [24], suggesting some factors could 
moderate the association between OA and mortality. Second, it was not possible to stratify our meta-analysis 
results according to gender, although it is known that women are at higher risk of OA and its complications [52]. 
Third, no study included considered nor the duration of OA at inclusion, nor its progression (clinically or 
radiologically) neither the incidence of new cases within the follow-up period. It is therefore unclear whether OA 
disease progression influenced the outcomes. Fur- thermore, there was no record as what treatments were 
prescribed and adhered to in the OA cohort, which clearly might influence mortality. Therefore it is unclear 
whether disease medication (or symptom modification) impacted on mortality. Fourth, there was some 
discrepancy in the prevalence of OA across the PRO.V.A. study and the meta-analysis. Reasons for this difference 
may include (i) the higher mean age of the PRO.V.A. cohort and (ii) the potential higher prevalence of OA in Italy 
than in other countries [6]. Fifth, we did not assess the association of OA with specific cause mortality other than 
CVD mortality. This was because there remains limited evidence on other cause mortality for people with OA. 
Consequently such analyses would have been underpowered and potentially meaningless. However, this should be 
considered in the future once more studies are published in this area. Finally, the analyses pertaining to site-
specific OA are preliminary and should be interpreted with cautious. These are based on a limited number of 
studies for each outcome, and appeared to be contrasting (lower limbs OA seems to increase and hand OA seems 
to decrease the risk of death). Further analyses should be undertaken to re-explore the potential importance of 
joint location with mortality as more studies are published in this area  
The strengths of this article are that it is the first meta-analysis to (i) assess for the association between OA and 
mortality and (ii) has specifically explored for factors to explain for the  
heterogeneity in individual study results. This therefore provides important knowledge to increase the awareness 
of CVD in this population. This is important since CVD is potentially preventable through appropriate timely 
interventions [10] to impact on the health of people with osteoarthritis. Secondly, since the cohorts included in 
these analyses were large, the collective pooled analyses provided lower risk of committing a type two statistical 
error which would have occurred if these studies were interpreted individually. Finally, in the adjusted analyses, a 
number and wide variety of different confounders were included in the analysis to be able to answer our research 
question with these potential factors accounted for.  
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In conclusion, it appears that people with OA are at increased risk of CVD-specific mortality while the association 
with overall mortality is less clear. Additional prospective research is required to further explore the relationship 
between OA and mortality.  
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Legend to Figures 
 
Figure 1. Meta-analysis and pooled hazard ratios of mortality in participants with osteoarthritis 
from prospective cohort studies (*, for this study the estimate was obtained by pooling within-study 
risks for symptomatic and radiographic osteoarthritis; **, for this study the estimate was obtained 
by meta-analysing within-study risks for different joints after pooling hazard ratios for only 
symptomatic, only radiographic and painful radiographic osteoarthritis). 
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Table 1. Baseline characteristics by diagnosis of osteoarthritis at baseline: the PRO.V.A. study.   
 
*Unless otherwise specified, p values are adjusted for age and gender using a general linear model 
or logistic regression, as appropriate.  
†Not adjusted for age.  
‡Not adjusted for gender.  
 
Abbreviations: ADL: activities of daily living; BMI: body mass index; COPD: chronic obstructive 
pulmonary disease; CVD: cardiovascular diseases; GDS: Geriatric Depression Scale; GNRI: 
Geriatric Nutrition Risk Index; MMSE: Mini Mental State Examination; OA: osteoarthritis; SD, 
standard deviation.  
  
Patients’ characteristics  OA 
(n=1,858) 
No OA 
(n=1,069) 
p value* 
Age (years), Mean±SD 77.5±7.9 74.6±7.6 <0.001† 
Female gender, % 66.4 48.2 <0.001‡ 
General and anthropometric characteristics     
Alcohol drinking, % 65.1 72.8 <0.001 
Current smokers, % 6.3 13.0 <0.001 
Educational level > 5 years, % 13.0 17.4 0.002 
Physical activity≥4 h/week, %  19.0 22.8 <0.001 
Monthly income (>500 €), % 36.1 44.7 <0.001 
GNRI (score),  Mean±SD 105.6±5.7 106.5±5.6 0.048 
ADL (score),  Mean±SD 4.6±1.8 5.4±1.4 <0.001 
BMI (kg/m2),  Mean±SD 28.0±4.8 26.8±4.2 <0.001 
GDS (score),  Mean±SD 9.5±6.0 8.1±5.0 <0.001 
MMSE (score),  Mean±SD 22.3±7.0 23.8±6.2 0.51 
Medical conditions    
Frailty, % 12.6 4.9 <0.001 
Fractures, % 11.6 5.9 <0.001 
Diabetes, % 17.7 14.7 0.03 
Hypertension, % 76.3 70.8 0.001 
Orthostatic hypotension, % 34.1 28.8 0.004 
CVD, % 25.5 20.4 0.002 
COPD, % 10.0 9.1 0.44 
Cancer, % 7.9 7.4 0.67 
Number of drugs, Mean±SD 3.1±2.2 2.4±2.1 <0.001 
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Table 2: Association of osteoarthritis (OA) with the onset of all-cause mortality in the PRO.V.A. 
study cohort. 
 
 
Data are presented as hazard ratios and 95% confidence intervals [HR (95%CI)]. 
 
*The fully-adjusted model  includes: age (continuous); gender; body mass index (continuous); 
educational level (< 5 vs. >5 years); alcohol drinking (yes vs. no); monthly income (>500 vs. <500 
€); physical activity level (>4 vs. <4 h/week); presence at baseline of cardiovascular diseases, 
fractures, chronic obstructive pulmonary disease, orthostatic hypotension, hypertension, diabetes, 
frailty, cancer (all yes vs. no); number of medications (continuous); smoking status (current vs. 
no/former); Activities of Daily Living, Mini-Mental State, Geriatric Depression Scale, Geriatric 
Nutrition Risk Index scores (all as continuous).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Events 
(N) 
Participants 
(N) 
Unadjusted 
HR (95%CI) 
p– 
value 
Fully-adjusted * 
HR (95%CI) 
p–
value 
No OA 241 1,068 reference reference 
Presence of OA 504 1,857 1.16 (0.96-1.40) 0.12 0.95 (0.78-1.16) 0.59 
Hand OA 180 695 1.13 (0.89-1.43) 0.33 1.00 (0.78-1.29) 0.99 
Hip OA 231 966 1.07 (0.87-1.33) 0.52 0.96 (0.77-1.20) 0.70 
Knee OA 140 549 1.05 (0.81-1.35) 0.74 0.86 (0.66-1.12) 0.27 
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Table 3. Characteristics of the studies according to the presence of osteoarthritis or not.   
 
First 
author, 
year 
 
Continent 
(Country) Setting 
Diagnosis  
criteria for  
OA 
OA N Mean age (SD) 
Females 
(N) 
CVD  
(N) 
Mean BMI 
(SD) 
Death 
ascertainment 
Follow-
up 
(years) 
Adjustments 
(N) 
NOS 
score 
Barbour, 
2015 
North America 
(USA) Community Radiological 
Yes 635 72.7 (5.3) 635 53 26.7 (4.6) Phone calls + 
death certificates 16 7 8 No 7254 71.2 (5.0) 7254 464 26.5 (4.6) 
Castano 
Betancourt, 
2013 
Europe (The 
Netherlands) Community Radiological 
Yes 4733 > 55 2721 -- -- 
GP records 5 11 7 
No 6261 > 55 -- -- -- 
Cacciatore, 
2014 Europe (Italy) Community 
Clinical + 
Radiological 
Yes 698 74.8 (6.5) 559 -- 27.0 (5.1) 
Death certificates 12 13 6 
No 590 72.7 (6.9) 175 -- 25.8 (4.5) 
Haugen, 
2015 
North America 
(USA) Community 
Clinical + 
Radiological 
Yes 1162 66.3 (7.6) 422 55 27.9 (4.6) Linkage to 
different 
registries 
20 14 9 
No 622 57.6 (6.4) 303 37 27.4 (4.5) 
Kluzek, 
2015 Europe (UK) Community 
Clinical + 
Radiological 
Yes 689 57.5 (6.0) 709 31 -- 
Death certificates 23 13 9 
No 940 55.0 (5.7) 940 35 -- 
Liu, 2015 Asia (China) Community Clinical + Radiological 
Yes 244 62.0  (10.2) 163 -- 23.7 (3.7) Interview with 
relatives 8 7 8 No 1806 56.0 (7.7) 877 -- -- 
PRO.V.A. 
study Europe (Italy) Community 
Clinical + 
Radiological 
Yes 1857 77.5 (7.9) 1233 473 28.0 (4.8) 
Death certificates 4 21 7 
No 1068 74.6 (7.6) 515 218 26.8 (4.2) 
 
Abbreviations: BMI: body mass index; CVD: cardiovascular disease; GP: general practitioner; NOS score: Newcastle Ottawa scale score; OA: 
osteoarthritis; SD: standard deviation.  
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 Table 4. Adjusted all-cause mortality risk for strata of different moderators  
Moderator Strata Analysis details Adjusted HRs 
Continent 
 
 
Europe 
 
 
 
 
Other 
 
 
 
 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
P-value * 
1.18 (1.08-1.28) 
<0.001 
47% (0.13) 
4 
 
1.06 (0.80-1.25) 
0.68 
82% (0.004) 
3 
 
0.82 
Study quality† 
 
 
NOS score ≤7 
 
 
 
 
NOS score >7 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
P-value* 
1.14 (0.96-1.36) 
0.13 
64% (0.06) 
3 
 
1.09 (0.84-1.39) 
0.53 
74% (0.01) 
4 
 
0.74 
Number of adjustments 
† 
 
 
<13 
 
 
 
 
≥13 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
P-value * 
1.18 (1.10-1.27) 
<0.0001 
8% (0.34) 
3 
 
1.00 (0.81-1.26) 
0.95 
63% (0.05) 
4 
0.18 
Follow-up duration † 
 
 
<15 
 
 
 
 
≥15 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
P-value* 
1.17 (1.00-1.38) 
0.05 
53% (0.09) 
4 
 
1.02 (0.76-1.36) 
0.91 
79% (0.008) 
3 
 
0.39 
20  
 
 
Bolded HR values: p<0.05 
Abbreviations: HR: hazard ratio; NOS: Newcastle-Ottawa Scale 
* The P-value for the t-test between the two statistical analysis strata according to meta-regression 
procedure. 
† Stratification was performed by median NOS score, median follow-up time and median number of 
adjustments as appropriate.  
 
Diagnosis of death 
 
 
Death 
certificates 
 
 
 
 
Others 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
P-value * 
1.18 (1.08-1.28) 
<0.001 
47% (0.13) 
4 
 
1.06 (0.80-1.25) 
0.68 
82% (0.004) 
3 
 
0.82 
Diagnosis of 
osteoarthritis 
 
 
Radiological + 
clinical 
 
 
 
Only 
radiological 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
P-value* 
1.07 (0.85-1.34) 
0.57 
65% (0.02) 
5 
 
1.18 (1.09-1.27) 
<0.001 
19% (0.27) 
2 
 
0.42 
Sites investigated 
 
 
Only one joint 
 
 
 
 
More joints 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
P-value * 
1.06 (0.80-1.41) 
0.68 
82% (0.004) 
3 
 
1.18 (1.08-1.28) 
<0.001 
47% (0.13) 
4 
 
0.61 
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Supplementary Table 1: Search terms adopted for the search strategy  
1. Osteoarthritis 
2. Arthritis 
3. Osteo$ 
4. AND 
5. Mortality 
6. Death 
7. premature mortality 
8. 1+5 
9. 1+6 
10. 1+7 
11. 2+5 
12. 2+6 
13. 2+7 
14. 3+5 
15. 3+6 
16. 3+7  
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Supplementary Table 2. Newcastle-Ottawa Scale (NOS) table: methodological quality of cohort studies included in the meta-analysis* 
First author, 
publication year 
 
Representativene
ss 
of the exposed 
cohort 
Selection of 
the 
unexposed 
cohort 
Ascertainmen
t 
of exposure† 
Outcome of 
interest not 
present at 
start of 
study‡ 
Control for 
important 
factor or 
additional 
factor§ 
Assessment 
of outcome 
Follow-up 
long 
enough for 
outcome 
to occur|| 
 
Follow-up 
of cohort 
adequate 
Total 
quality 
score 
Barbour, 2015 * * * * * * * * 8 
Castano Betancourt, 2013 * - * * * * * * 7 
Cacciatore, 2014 * * - - * * * * 6 
Haugen, 2015 * * * * ** * * * 9 
Kluzek, 2015 * * * * ** * * * 9 
Liu, 2015 * * * - ** * * * 8 
PRO.V.A. study * * - * ** * - * 7 
 
* A study could be awarded a maximum of one star for each item except for the item Control for important factor or additional factor. The 
definition/explanation of each column of the Newcastle-Ottawa Scale is available at 
http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.  
 
† For this index, one star was given if in Method section OA was defined according with standard criteria or radiological exams for all 
participants were reported. 
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‡ Being outcome of interest mortality, we took as outcome of interest for assessment of quality if specific-cause mortality was reported or 
autopsy was used for the ascertainment of the death.  
§ A maximum of 2 stars could be awarded for this item. Studies that controlled their survival analyses for at least five confounders received one 
star, whereas studies presenting data according to site of OA (hand, hip and/or knee) received an additional star. 
|| A cohort study with a mean/median follow-up time ≥5 y (60 months) takes one star; if the mean follow-up is not clearly indicated: no star. 
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Supplementary Table 3. Type and number of adjustments (in addiction of osteoarthritis) for each study. 
 
First author, 
publication year 
 
Adjustments Number of adjustments 
Barbour, 2015 Age, body mass index, education, smoking, health status, diabetes, stroke 7 
Castano Betancourt, 2013 Age, gender, cohort study, smoking, diabetes, cardiovascular diseases, dementia, body mass index, walking disability, analgesic-use, functional limitations 11 
Cacciatore, 2014 
Age, gender, body mass index, waist circumference, heart rate, pulse blood pressure, 
Charlson co-morbidity index, number of drugs, use of not steroidal anti-inflammatory 
drugs, corticosteroids, disability, geriatric depression scale, frailty 
13 
Haugen, 2015 
Age, sex, cohort, body mass index, total cholesterol:HDL ratio, current lipid lowering 
treatment, hypertension, current antihypertensive treatment, elevated fasting or non-
fasting blood glucose, current anti-diabetic treatment (oral or insulin), current use of not 
steroidal anti-inflammatory drugs, daily use of aspirin, current/previous smoking, 
alcohol use 
14 
Kluzek, 2015 
Age, smoking, total cholesterol, HDL-cholesterol, systolic blood pressure,  use of anti-
hypertensive drugs, occupation, body mass index, hormonal replacement therapy use, 
past physical activity, current/previous cardiovascular disease, not steroidal anti-
inflammatory drugs, plasma glucose levels 
13 
Liu, 2015 Age, sex, body mass index, income level, education, levels of occupational physical activity, comorbidities 7 
PRO.V.A. study 
Age, sex, body mass index, diabetes, hypertension, orthostatic hypotension, 
cardiovascular diseases, fractures, chronic obstructive pulmonary disease, cancer, 
educational level, smoking habits, monthly income, alcohol drinking, physical activity 
level, activities of daily living preserved, geriatric depression scale score, mini-mental 
state examination score, Geriatric Nutrition Risk Index, number of drugs, frailty 
21 
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Supplementary Figure 1. PRISMA flow diagram of systematic review of literature 
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